Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to content Skip to footer

Insights+: The US FDA New Drug Approvals in January 2024

Shots: 

  • The US FDA approved 1 NDA in January 2024, leading to treatments for patients and advances in the healthcare industry 
  • In January 2023, Zelsuvmi was approved by the US FDA for the Treatment of Molluscum Contagiosum 
  • PharmaShots has compiled a list of US FDA-approved drugs in the month January 2024 

1. Ligand Pharmaceuticals’ Zelsuvmi Receives the US FDA’s Approval for the Treatment of Molluscum Contagiosum 

    Active Ingredient: Berdazimer Topical Gel 

    Approved: Jan 8, 2024 

    Company: Ligand Pharmaceuticals                         

    Disease: Molluscum Contagiosum  

  • Zelsuvmi (berdazimer topical gel, 10.3%) received the US FDA’s approval as a novel drug for the treatment of molluscum infections in adults & pediatric patients aged ≥1yrs. Zelsuvmi is expected to be commercially available in the US by H2’24 
  • The company evaluated the safety & effectiveness of the US FDA-approved Zelsuvmi in P-III clinical trials (B-SIMPLE 4) & (B-SIMPLE 2) among patients (n=1,598) with Molluscum Contagiosum that depicted Zelsuvmi’s ability to reduce lesion counts & was well tolerated as QD dosage in patients 
  • Zelsuvmi is a nitric oxide (NO) releasing agent that has been attributed to have antiviral properties. With an unknown mechanism of action Zelsuvmi will be used as a topical treatment in patients above the age of 1year (pediatric & adults) 

Note:  

  • According to the FDA’s January 2024 approval list, the combination therapy of Dolutegravir, Emtricitabine, Tenofovir, and Alafenamide was also approved; however, no PR was available 

Related Post: Insights+: The US FDA New Drug Approvals in December 2023 

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]